AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth CareGeographicals
Bone Marrow TransplantationBone MarrowTransplantation, HomologousBone Marrow CellsGraft vs Host DiseaseTransplantation, AutologousTissue DonorsLiver TransplantationKidney TransplantationGraft SurvivalWhole-Body IrradiationTissue and Organ ProcurementAnemia, AplasticLeukemiaHematopoietic Stem Cell TransplantationTransplantation ConditioningLiving DonorsBone and BonesOrgan TransplantationTransplantation ChimeraMedical TourismHistocompatibility TestingTransplantationGraft RejectionBone Marrow PurgingTreatment OutcomeBusulfanHematopoietic Stem CellsHistocompatibilityLung TransplantationTime FactorsHematologic NeoplasmsBone Marrow DiseasesRetrospective StudiesImmunosuppressive AgentsCyclophosphamideTransplantation, IsogeneicRecurrenceHematopoiesisLeukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic, BCR-ABL PositiveBone Marrow ExaminationCombined Modality TherapyMice, Inbred C57BLRadiation ChimeraImmunosuppressionPrecursor Cell Lymphoblastic Leukemia-LymphomaWaiting ListsPostoperative ComplicationsBone Marrow NeoplasmsCytomegalovirus InfectionsHepatic Veno-Occlusive DiseaseRemission InductionGraft vs Host ReactionAcute DiseaseHeart TransplantationLeukemia, MyeloidCyclosporineTransplantation ImmunologyLymphoma, Non-HodgkinLymphocyte DepletionSurvival AnalysisHLA AntigensMyelodysplastic SyndromesColony-Forming Units AssayT-LymphocytesStem Cell TransplantationLeukocyte TransfusionHematologic DiseasesChimeraSevere Combined ImmunodeficiencyBone RemodelingCadaverFollow-Up StudiesNuclear FamilySurvival RateLymphocyte TransfusionActuarial AnalysisOpportunistic InfectionsCell DifferentiationAntineoplastic Combined Chemotherapy ProtocolsImmunocompromised HostFatal OutcomeLeukocyte CountPancytopeniaLymphomaDisease-Free SurvivalSpleenMultiple MyelomaAntilymphocyte SerumFlow CytometryMice, Inbred BALB CGraft vs Tumor EffectGranulocyte Colony-Stimulating FactorHodgkin DiseasePrognosisGraft vs Leukemia EffectCells, CulturedBone DensityCytarabine
Hematological MalignanciesChemotherapyDonorUmbilical cordMultiple myelomaOncologyCancersHSCTPost-transplantClinicalLymphomaHematology1992Allogeneic transplantRecipientsSolid tumorsDisordersAdultsOutcomesDana-FarberTherapiesAcute lymphocyPatient'sEngraftmentPeripheral blood stem cellHaploidentical2018ImmunotherapyCIBMTRLeukemiaCellular therapy programAutologous transplantSyngeneicDonor'sCell therapy for boneAplastic anemiaDONORSImmune deficienciesSurvivalTreatmentsMyelodysplastic syndromesPediatric bloodSpongyDiseasesMyeloid
Hematological Malignancies5
  • The indications for bone marrow transplantation are increasing from hematological malignancies to more recently solid tumours and numerous autoimmune conditions. (telixpharma.com)
  • a broad range of disorders for which transplantion of HPCs from an adult donor is also successful, including hematological malignancies, solid tumors, constitutional and acquired bone marrow failure syndromes, hemoglobinopathies, congenital immune deficiencies, and inherited disorders of metabolism (Gluckman et al. (nationalacademies.org)
  • Allogeneic hematopoietic cell transplantation (allo-HCT) has lifesaving potential for patients with hematological malignancies and bone marrow disorders, the authors wrote. (genengnews.com)
  • Nevertheless, targeting solid tumors is more challenging than targeting hematological malignancies because of tumor histopathological characteristics, shortage of specific antigens and local strong immunosuppressive microenvironment [ 4 ]. (ijbs.com)
  • In the first quarter of this year, we made significant progress on key initiatives across all functions of our business, starting with omidubicel, a potentially transformative treatment option for patients with hematological malignancies," said Julian Adams, Ph.D., chief executive officer of Gamida Cell. (biospace.com)
Chemotherapy9
  • Doctors extract stem cells from your blood or bone marrow, place them in frozen storage, and re-infuse them back into your body following high-dose chemotherapy to eliminate blood cancers. (bidmc.org)
  • The purpose is to deliver chemotherapy, immunotherapy, and/or radiation to eliminate malignancy, prevent rejection of new stem cells, and create space for the new cells. (medscape.com)
  • Under his leadership, Jefferson's Department of Medical Oncology more than tripled in size, established a nationally recognized senior adult oncology program as well as an embedded Supportive Medicine and Survivorship Program, and has launched efforts to expand home chemotherapy administration and other cutting-edge care delivery models. (phacilitate.com)
  • Treatment includes chemotherapy and often stem cell transplantation , either from the patient's own bone marrow (autologous) or sometimes from another person's bone marrow (allogeneic). (dana-farber.org)
  • Her program of research is focused on the neurotoxic and myotoxic effects of chemotherapy and biotherapy on individuals undergoing cancer treatment. (nursingworld.org)
  • An important and unanswered question concerns the impact of the number of conventional AML chemotherapy induction cycles to achieve first complete remission on transplant outcomes. (ascopost.com)
  • Because of the patient's risk status, the physicians intended to perform allogeneic stem cell transplantation after induction and consolidation chemotherapy, which was scheduled to end in January 2013, and a conditioning chemotherapy regimen, which was planned to be given in March. (cdc.gov)
  • Currently, recipients that undergo BMT are treated with toxic agents such as radiation and chemotherapy in order to in order to eliminate their own blood forming stem cells and permit the donor cells to take and develop. (ca.gov)
  • Treatment options include transfusions, drug therapy, chemotherapy, and blood or bone marrow stem cell transplants. (medlineplus.gov)
Donor24
  • Cells for HSCT may be obtained from the patient himself or herself (autologous transplant) or from another person, such as a sibling or unrelated donor (allogeneic transplant) or an identical twin (syngeneic transplant). (medscape.com)
  • The National Marrow Donor Program (NMDP), founded in 1986, and the World Marrow Donor Association (WMDA), founded in 1988, were established to (1) locate and secure appropriate unrelated-donor HSCT sources for patients by promoting volunteer donation of bone marrow and peripheral blood stem cells in the community and (2) promote ethical practices of sharing stem cell sources by need, rather than by geographic location of the donor. (medscape.com)
  • Typically, the therapy entails removing stem cells from the bone marrow or blood of a cancer patient or from a donor. (floridatrend.com)
  • This global trial evaluated omidubicel versus standard cord blood in patients with hematologic malignancies, who needed a bone marrow transplant, but did not have a suitable match donor. (seekingalpha.com)
  • The collaboration supports NiCord ® , Gamida Cell's investigational cell therapy, which has the potential to serve as a universal bone marrow donor source for patients with hematologic malignancies, or blood cancers, and bone marrow failure disorders requiring bone marrow transplantation. (bethematchbiotherapies.com)
  • Despite the curative potential of bone marrow transplants, it is estimated that more than 40 percent of eligible patients in the U.S. do not receive one for various reasons, including difficulty in finding a matched donor. (bethematchbiotherapies.com)
  • 1 NiCord is designed to potentially serve as a universal alternative to existing donor sources for bone marrow transplant. (bethematchbiotherapies.com)
  • Our two organizations share the belief that new cell therapies are needed not only to improve outcomes for patients undergoing stem cell transplants but also to offer patients unable to find a matched donor the chance for a successful transplant," stated Julian Adams, Ph.D., chief executive officer of Gamida Cell. (bethematchbiotherapies.com)
  • Backed by the industry-leading experience of the National Marrow Donor Program/Be The Match , and a research partnership with the CIBMTR ® (Center for International Blood and Marrow Transplant Research ® ), the organization designs solutions that advance cell and gene therapies in any stage of development. (bethematchbiotherapies.com)
  • And even when a bone marrow transplant is curative for leukemia or lymphoma, GVHD-in which T cells in the donor graft attack the recipient's own tissues-can still be fatal. (genengnews.com)
  • One of the earliest reports on the utility of the adoptive transfer of donor lymphocytes for control of residual/relapsed malignancy after allogeneic transplantation. (phacilitate.com)
  • Here, we report transmission of dengue virus to a peripheral blood stem cell recipient by a donor who had recently traveled to an area to which the virus is endemic. (cdc.gov)
  • The 24-year-old woman, who was registered as a volunteer donor in the German Bone Marrow Donor Registry, was selected. (cdc.gov)
  • However, the donor was unable to postpone her trip, and the recipient was in urgent need of the transplant. (cdc.gov)
  • Standard leukopheresis processing of blood from the donor was performed without problems. (cdc.gov)
  • A second apheresis or a bone marrow collection was considered, but neither was performed because the clinical condition of the donor worsened. (cdc.gov)
  • After being informed about possible infection of the donor, the transplant physicians administered immunoglobulin to the recipient intravenously. (cdc.gov)
  • Ramos CA " Striking the right balance: optimizing conditioning regimens for unrelated donor bone marrow transplant for severe aplastic anemia. . (bcm.edu)
  • Gurkan E, Patah PA, Saliba RM, Ramos CA, Anderson BS, Champlin R, de Lima M, Lichtiger B " Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation. . (bcm.edu)
  • First, the use of autologous hematopoietic stem cells for gene therapy obviates the need for a matched bone marrow donor since each individual would serve as his or her own bone marrow stem cell donor. (nih.gov)
  • This study compared the effects of pre-transplantation minimal residual disease (pre-MRD) on outcomes in AML patients who underwent human leukocyte antigen-matched sibling donor transplantation (MSDT) or who received unmanipulated haploidentical allografts. (biomedcentral.com)
  • Unfortunately, the way the transplants are currently performed, with toxic treatments to prepare the children to accept the donor cells and the side effects caused by lymphocytes that contaminate standard blood cell grafts reduces the likelihood of successful cure. (ca.gov)
  • Our objective is to test the antibody that targets human CD117 to safely prepare children with SCID to accept blood forming stem cells from a donor. (ca.gov)
  • If the antibody treatment results a stronger blood system originating from a donor in SCID patients, this result would prove that the antibody could be used to optimize engraftment of gene-therapy modified cells and could be applied to the treatment the many other diseases that need a BMT. (ca.gov)
Umbilical cord3
  • Umbilical cord blood is a rich source of these committed progenitor cells and, presumably, multipotent HPCs (Knudtzon, 1974). (nationalacademies.org)
  • The company anticipates submitting a Biologics License Application (BLA) to the FDA in the fourth quarter of this year, based on the results of an international, randomized Phase 3 study of omidubicel that was designed to evaluate the safety and efficacy of omidubicel in patients with hematologic malignancies undergoing a bone marrow transplant compared to patients who received a standard umbilical cord blood transplant. (biospace.com)
  • and umbilical cord blood (PUCB), capable of 2017), associated with the results of the procedure restoring spinal cord function and immunology of and require a process of hospitalization and patients with indication for transplantation, with the prolonged hospital recovery. (bvsalud.org)
Multiple myeloma6
Oncology8
  • The Division of Oncology cares for patients with various malignancies. (nymc.edu)
  • Dr. Hari serves as the Director of the Adult Bone and Marrow Transplant Programs for Froedtert Hospital and Section Head for Hematologic Malignancies and Transplantation in the Division of Hematology and Oncology in the Department of Medicine. (curetalks.com)
  • He completed his training in Internal Medicine and Hematology at premier institutes in United Kingdom and Medical Oncology Transplantation at the Medical College of Wisconsin. (curetalks.com)
  • We found that just a single dose of antibodies to block the Notch signaling pathway, given immediately before the transplant, was able to prevent gastrointestinal GVHD, without impairing immune function in the rest of the body," said Ivan Maillard, MD, PhD, a professor of Medicine and vice chief for research in hematology-oncology at the Perelman School of Medicine at the University of Pennsylvania. (genengnews.com)
  • Dr. Seth Maliske specializes in hematology, oncology and blood and bone marrow transplants. (sanfordhealth.org)
  • Before joining LLS, he spent 15 years at Nemours Children's Health, where he built the Blood and Bone Marrow Transplant Program and most recently served as chief of the Division of Hematology and Oncology, Director of the Moseley Foundation Institute for Cancer and Blood Disorders, and Vice Chairman for Research in the Department of Pediatrics at the Sidney Kimmel Medical College at Thomas Jefferson University. (lls.org)
  • Dr. Kolb has been the principal or co-principal investigator of numerous studies and grants, including clinical trials with the Children's Oncology Group, the Nemours NCI Community Oncology Research Program (NCORP) and the Center of Biomedical Research Excellence (COBRE), which awarded Nemours Children's Health a $10.5 million grant to establish the Delaware Comprehensive Sickle Cell Research Center. (lls.org)
  • The Dana-Farber/Boston Children's Cancer and Blood Disorders Center is an integrated pediatric hematology and oncology program through Dana-Farber Cancer Institute and Boston Children's Hospital. (childrenshospital.org)
Cancers12
  • David G. Maloney (born 25 November 1954) is an oncologist and researcher at Fred Hutchinson Cancer Research Center and the University of Washington who specializes in developing targeted immunotherapies for the treatment of blood cancers. (wikipedia.org)
  • Further research by Maloney has continued to develop antibody-based therapeutic strategies for blood cancers. (wikipedia.org)
  • In the field of hematopoietic stem cell transplantation, Maloney has played a role in the development of lower-toxicity, non-myeloablative techniques for the treatment of blood cancers. (wikipedia.org)
  • Tampa General's new bone marrow transplant unit targets aggressive blood cancers. (floridatrend.com)
  • Under the terms of the collaboration agreement, Gamida Cell and Be The Match BioTherapies will explore opportunities to work together across Gamida Cell's ongoing clinical development program for NiCord, including the Phase 3 clinical study in patients with high-risk blood cancers. (bethematchbiotherapies.com)
  • His career has focused on the care of patients with blood cancers, particularly those undergoing bone marrow or peripheral blood stem cell transplants. (phacilitate.com)
  • Dana-Farber/Boston Children's offers internationally renowned care for children with cancers of the blood and immune system. (dana-farber.org)
  • He was recruited to UNC in 1992 to launch the bone marrow and stem cell transplant program - bringing important treatments for patients with advanced blood cancers, including leukemia and lymphoma - after launching a bone marrow transplant program at the University of California San Diego four years prior in 1988. (unclineberger.org)
  • The emerging therapeutic approach of CAR-T cell therapy has sparked great interests, extensive studies in preclinical and clinical trials have revealed encouraging therapeutic efficacy in treating a variety of cancers, particularly in treating B-cell hematologic malignancies with CD19 CAR-T cells [ 3 ]. (ijbs.com)
  • BOSTON--( BUSINESS WIRE )-- Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today reported financial results for the quarter ended March 31, 2021. (biospace.com)
  • Thousands of patients undergo BMT yearly to successfully cure cancers or disorders of blood formation. (ca.gov)
  • These diseases include, but are not limited to sickle cell and Fanconi's anemia, autoimmune diseases like diabetes and multiple sclerosis, and cancers that originate from the blood system such as leukemias and lymphomas. (ca.gov)
HSCT11
  • Hematopoietic stem cell transplantation (HSCT) involves the intravenous infusion of hematopoietic stem cells in order to reestablish blood cell production in patients whose bone marrow or immune system is damaged or defective. (medscape.com)
  • This, along with the development of unrelated cord blood transplantation and familial haploidentical transplantation methods, have improved the likelihood of finding an appropriate HSCT source in a timely manner. (medscape.com)
  • TLX66 ( 90 Y-besilesomab), is an investigational asset granted orphan drug designation (ODD) status in Europe and the United States for bone marrow conditioning for hematopoietic stem cell transplantation (HSCT), a broad clinical indication. (telixpharma.com)
  • CAMBRIDGE, Mass., July 17, 2018 - Gamida Cell , a leading cellular and immune therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for NiCord as a treatment for hematopoietic stem cell transplantation (HSCT). (shavitcapital.com)
  • Gamida Cell was previously granted orphan drug designation for NiCord by the FDA as a treatment for several hematologic malignancies, and by the European Medicines Agency (EMA) as a treatment for HSCT. (shavitcapital.com)
  • The ability to correct genetic hematopoietic diseases by gene therapy has a number of advantages over current therapies that involve allogeneic hematopoietic stem cell transplantation (HSCT). (nih.gov)
  • We are evaluating whether allogeneic HSCT can reconstitute normal hematopoiesis in MonoMAC and reverse the hematological abnormalities in MDS, if MDS is present at the time of transplant. (nih.gov)
  • Attention and working memory (WM) findings in pediatric patients prior to hematopoietic stem cell transplant (HSCT) for hematologic malignancies. (upenn.edu)
  • Hematopoietic stem cell transplantation (HSCT) affects serious risks for the patient, including death. (bvsalud.org)
  • HSCT make it an aggressive process, causing consists of painless intravenous infusion of healthy toxicity and can generate significant complications hematopoietic stem cells (HSC) extracted from bone and several side effects adding feelings of worry, marrow (BM), peripheral blood (PB) and placental anguish, anxiety, among others (KUBA et al. (bvsalud.org)
  • Also, drastic changes in daily living habits, qualified and responsible for the implementation of changes in body image, long duration of treatment, HSCT since 2004, agreed to the Brazilian Unified periods of hospitalization and protective isolation, Health System, which meets the needs of the feeling of loss of control, fear of death and lack of patients with an indication for transplantation. (bvsalud.org)
Post-transplant5
  • We are talking to Dr. Parameswaran Hari on his recent research on post-transplant outcomes in high risk myeloma patients. (curetalks.com)
  • The study, headed by researchers at Penn Medicine and Dana-Farber/Boston Children's Cancer and Blood Disorders Center, demonstrated that antibody blockade of the Notch signaling pathway improved post-transplant survival and protected against gastrointestinal GVHD in particular. (genengnews.com)
  • The acute or fulminant form of the disease (aGvHD) is normally observed within the first 10 to 100 days post-transplant, [9] [10] and is a major challenge to transplants owing to associated morbidity and mortality. (wikipedia.org)
  • Dr. Loren is particularly dedicated to enhancing transplant outcomes and post-transplant survivorship, showcasing expertise in fertility preservation. (radcliffecardiology.com)
  • Health-related quality of life in pediatric bone marrow transplant patients: Pre- and post-transplant ratings. (upenn.edu)
Clinical10
  • NiCord, Gamida Cell's lead clinical program, is under development as a universal bone marrow transplant solution for patients with high-risk hematologic malignancies. (bethematchbiotherapies.com)
  • Blood and Marrow Transplant Research [CIBMTR] in 2004), the European Research Project on Cord Blood Transplantation (Eurocord) in 1993, and the Japanese Cord Blood Banking Network in 1996-expedited the clinical evaluation of the efficacy and safety of transplantation of cord blood from unrelated donors. (nationalacademies.org)
  • As the clinical nurse specialist on the adult inpatient transplant unit, I work with the nurse leader and clinical staff to promote a culture of excellence in the care of our patients. (mskcc.org)
  • In addition to his contributions to stem cell transplant research and clinical care, Shea was critical in the development of the SECU Family House at UNC Hospitals , an affordable home in Chapel Hill where patients and their families can stay while receiving treatment at UNC. (unclineberger.org)
  • The company also highlighted progress with omidubicel , an advanced cell therapy with positive Phase 3 clinical data, as a potentially life-saving treatment option for patients in need of an allogeneic hematopoietic stem cell (bone marrow) transplant, and GDA-201 , a natural killer (NK) cell immunotherapy in Phase 1/2 development for patients with non-Hodgkin lymphoma (NHL). (biospace.com)
  • Additionally, the study met key secondary endpoints related to the speed of platelet engraftment, decrease in infections and reduction in hospitalizations, all significant clinical measures in bone marrow transplant. (biospace.com)
  • Her focus lies in conducting clinical trials related to hematologic malignancies and allogeneic hematopoietic cell transplantation. (radcliffecardiology.com)
  • Dr. Loren has served as co-Chair of the Regimen Related Toxicity Committee and contributed significantly to the Bone Marrow Transplant Clinical Trials Network (BMT-CTN), including acting as the site Principal Investigator for various trials. (radcliffecardiology.com)
  • We have brought together world experts in transplantation, protein development and clinical study design who have the shared objective of bringing the technology of antibody targeting stem cells to patients. (ca.gov)
  • Acquired and germline predisposition to bone marrow failure: Diagnostic features and clinical implications. (cdc.gov)
Lymphoma6
  • The program, which is accredited by the Foundation for the Accreditation of Cellular Therapy , has pioneered a tandem stem cell transplant for Hodgkin lymphoma, reduced intensity conditioning treatments utilizing the drug mitoxantrone, ara-C and pentostatin and refrigerated marrow storage techniques that have led to wide acclaim. (nymc.edu)
  • Children and teens with rare childhood non-Hodgkin lymphoma are treated at Dana-Farber/Boston Children's Cancer and Blood Disorders Center through the Childhood Lymphoma Program in our Childhood Hematologic Malignancy Center . (dana-farber.org)
  • Because the chromosomal t(14;18) translocation is found in the majority of patients with follicular lymphoma, bone marrow aspiration and chromosome analysis can also help establish the diagnosis. (medscape.com)
  • Most patients with follicular lymphoma present at an advanced stage, and most patients have bone marrow involvement at diagnosis. (medscape.com)
  • and Director of the Pediatric Leukemia and Lymphoma Service and Pediatric Stem Cell Transplantation at The Children's Hospital at Montefiore, also in the Bronx. (lls.org)
  • The Dana-Farber/Boston Children's Hematologic Malignancy Center treats children with hematologic malignancies, including leukemia and lymphoma. (childrenshospital.org)
Hematology2
  • Positive data from the dose-escalation stage of the study, which was recently presented at the 2014 ASH (American Society of Hematology) Conference, has shown substantial mobilization of AML cancer cells from the bone marrow to the peripheral blood and robust apoptosis of these cells, as well as an excellent safety and tolerability profile. (technologynetworks.com)
  • To complement The ASCO Post 's continued comprehensive coverage of the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on allogeneic transplantation for hematologic neoplasms in adults. (ascopost.com)
19922
  • Couris says the unit's opening followed two years of planning, including consulting with Massachusetts General Hospital in Boston, which has had a bone marrow transplant program since 1992 and does about 150 transplants annually. (floridatrend.com)
  • Since beginning the BMCF in 1992, Christina has dedicated her life to improving the quality of life for cancer patients and bone marrow/Hematopoietic Cell Transplantation (HCT) transplant patients and their families. (bonemarrow.org)
Allogeneic transplant2
  • [11] About one-third to one-half of allogeneic transplant recipients will develop acute GvHD. (wikipedia.org)
  • Second, the use of the patient's own bone marrow cells for gene replacement does not result in graft-versus-host disease (GVHD), a major complication of current allogeneic transplant. (nih.gov)
Recipients3
  • The high numbers of leukocytes remaining in a unit of pRBCs during the storage process can fragment, deteriorate, and release cytokines, and they have been implicated as a cause of reactions to a current and subsequent blood transfusions in some transfusion recipients. (utmb.edu)
  • Bob has been a major supporter of bone marrow transplant recipients since the time of his own transplant in 1990. (bonemarrow.org)
  • Neurocognitive dysfunction in hematopoietic cell transplant recipients: Expert review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. (upenn.edu)
Solid tumors1
  • However, targeting solid tumors is more challenging than targeting B-cell malignancies with CAR-T cells because of the histopathological structure features, specific antigens shortage and strong immunosuppressive environment of solid tumors. (ijbs.com)
Disorders3
  • Dr. Saral's major accomplishments include being the first physician to use bone marrow transplantation in the treatment of AIDS-related malignancies and among the first to use it in the treatment of sickle cell anemia and other inherited blood disorders. (emory.edu)
  • Maillard, together with co-senior and co-corresponding author Leslie S. Kean, MD, PhD, a professor of pediatrics at Harvard Medical School and director of pediatric stem cell transplant at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, and lead author Victor Tkachev PhD, an assistant professor of surgery at Mass General Brigham, have long sought to prevent this fatal complication. (genengnews.com)
  • Therapies for these disorders (eg, intravenous immunoglobulin [IVIG], bone marrow transplantation, gene therapy) are very costly and require highly advanced facilities. (medscape.com)
Adults2
  • It's also among only a few programs nationally that offer transplantation to adults 70 and older. (floridatrend.com)
  • TLX66-CDx ( 99m Tc-besilesomab) is approved and marketed as Scintimun® by Telix's license partner in approximately 30 countries for scintigraphic imaging, in conjunction with other appropriate imaging modalities, for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis. (telixpharma.com)
Outcomes2
  • Currently, there is little information about the effects of MRD on transplant outcomes in haplo-SCT settings. (biomedcentral.com)
  • There may be differences in the anti-leukemia effects of haplo-SCT vs. MSDT [ 21 ], so this study investigated both the asso ciation of MRD status with outcomes in haplo-SCT and MDST settings and also possible differences in the transplant outcomes of patients with positive pre-MRD (as determined by MFC) who underwent haplo-SCT versus MDST. (biomedcentral.com)
Dana-Farber5
  • Dana-Farber/Boston Children's also offers a wide array of support services and programs for pediatric patients and their families during and after cancer treatment. (dana-farber.org)
  • The Dana-Farber/Boston Children's Stem Cell Transplant Center offers autologous and allogeneic stem cell transplants and is active in researching new stem cell techniques. (dana-farber.org)
  • Children with AML are treated at Dana-Farber/Boston Children's through our Leukemia Program . (childrenshospital.org)
  • The Leukemia Program also partners closely with Dana-Farber/Boston Children's Stem Cell Transplant Program - one of the most experienced stem cell transplant programs in the world - to make stem cell transplantation available to children with AML. (childrenshospital.org)
  • The Dana-Farber/Boston Children's Leukemia Program is one of the top pediatric leukemia centers in the world. (childrenshospital.org)
Therapies3
  • Bone marrow transplant and now cell therapies can significantly increase the chance of recovery," says Abraham Schwarzberg. (floridatrend.com)
  • Gamida Cell's work to bring a new therapeutic option to patients in need of a bone marrow transplant aligns with our core mission to help organizations deliver cellular therapies that save more lives and improve the quality of life for patients," said Amy Ronneberg, President of Be The Match BioTherapies. (bethematchbiotherapies.com)
  • I have expertise in novel therapies for acute myeloid leukemia, stem cell mobilization and homing, as well as stem cell transplantation. (rochester.edu)
Acute lymphocy1
Patient's2
  • First, T or NK cells are isolated from patient's or donor's blood. (nature.com)
  • A key milestone in a patient's recovery, neutrophil engraftment is a measure of how quickly the stem cells a patient receives in a bone marrow transplant are established and begin to make healthy new cells. (biospace.com)
Engraftment2
Peripheral blood stem cell1
Haploidentical1
  • Establishment of a reproducible platform for haploidentical transplantation which allowed T cell and stem cell dose to be consistently controlled and manipulated for therapeutic advantage. (phacilitate.com)
20181
Immunotherapy1
  • Located in downtown Tampa's burgeoning medical district - which TGH and the University of South Florida have been developing over the last four years - the unit is less than a dozen miles from Moffitt Cancer Center's Blood and Marrow Transplant and Cellular Immunotherapy Program center, which was established in 1989 and is one of the largest programs of its kind in the Southeast. (floridatrend.com)
CIBMTR3
  • So, to get to your question, Gary, the CIBMTR stands for Center for International Blood and Marrow Transplant Research. (curetalks.com)
  • So, CIBMTR has been in existence not with this same exact name, but since almost the mid 1970s when bone marrow transplantation was just being invented, and one of the pioneering places was the Medical College of Wisconsin. (curetalks.com)
  • Retrospective analysis by the Center for International Blood and Marrow Transplant Research (CIBMTR): Prompt complete remission plus consolidation therapy yields improved survival after allogeneic hematopoietic cell transplantation (allo-HCT) for patients with acute myeloid leukemia (AML) receiving a myeloablative conditioning regimen and not a reduced-intensity conditioning regimen. (ascopost.com)
Leukemia5
Cellular therapy program2
  • By adding a bone marrow transplant and cellular therapy program, we're giving the residents of the Tampa Bay region and Florida more options. (floridatrend.com)
  • Dr. Loren is the Director of Blood and Marrow Transplant in the Transplant and Cellular Therapy Program of the Abramson Cancer Center, a clinician in hematologic malignancies, and a Professor of Medicine. (radcliffecardiology.com)
Autologous transplant1
  • Conditions like systemic amyloid light chain amyloidosis (SALA), an orphan disease that is often treated by autologous transplant, could benefit from more tolerable conditioning regimens. (telixpharma.com)
Syngeneic1
Donor's4
  • Stem cell transplant - also called bone marrow transplant, in this procedure a donor's stem cells are transfused into your blood. (bidmc.org)
  • Before apheresis, the donor's blood count showed mild thrombocytopenia after G-CSF mobilization. (cdc.gov)
  • White blood cells of the donor's immune system which remain within the donated tissue (the graft) recognize the recipient (the host) as foreign (non-self). (wikipedia.org)
  • GvHD occurs when the donor's immune system's white blood cells reject the recipient. (wikipedia.org)
Cell therapy for bone2
  • 2020 was an important year for Gamida Cell as we made significant progress across our entire pipeline, including omidubicel, which is poised to become the first FDA approved cell therapy for bone marrow transplantation. (seekingalpha.com)
  • During the quarter, Gamida Cell continued to advance omidubicel, the first cell therapy for bone marrow transplant to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). (biospace.com)
Aplastic anemia1
  • As a person with a bone marrow failure condition, such as myelodysplastic syndromes (MDS), aplastic anemia , paroxysmal nocturnal hemoglobinuria (PNH), etc., you are already taking precautions to protect your compromised immune system. (aamds.org)
DONORS2
  • 2003). After the early success of transplantation of cord blood from related donors, cord blood banks were established to provide rapidly accessible, human leukocyte antigen (HLA)-typed units predominantly for transplantation of HPCs from unrelated donors. (nationalacademies.org)
  • With more than 6,000 transplants of cord blood from related and unrelated donors performed thus far, cord blood has emerged as an acceptable, alternative source of HPCs that has some advantages over adult sources of HPCs and the availability of which represents an important development in the field. (nationalacademies.org)
Immune deficiencies1
Survival2
  • The team confirmed that the Notch pathway involvement in GVHD was conserved across species, and demonstrated in their animal models that just a single dose of the DLL4-blocking antibody given immediately before stem cell transplantation greatly increased survival and prevented signs of GVHD in the intestines, but without causing global immunosuppression. (genengnews.com)
  • this should lead to better overall survival in both transplant and non-transplant patients. (medscape.com)
Treatments1
Myelodysplastic syndromes1
  • Myelodysplastic syndromes often do not cause early symptoms and are sometimes found during a routine blood test. (medlineplus.gov)
Pediatric blood2
  • Dr. Kolb has devoted his life's work to caring for children with pediatric blood cancer and conducting research to find cures. (lls.org)
  • Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation. (cdc.gov)
Spongy3
Diseases3
  • Our radiologists report on your imaging studies and our hematopathologists (pathologists who specialize in blood diseases) review the results of your biopsy. (bidmc.org)
  • Patients living with bone marrow failure diseases and their families and caregivers should continue to practice social distancing, frequently wash and sanitize hands, wear masks around others, and encourage others to wear masks around you. (aamds.org)
  • Patients with these diseases have been disproportionately affected by the COVID-19 pandemic with concerning mortality rates for patients who contract the virus and concerns about the efficacy of the available vaccines for bone marrow failure patients. (aamds.org)
Myeloid1